Clinical Trial Update: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

This is an open-label Phase 1/2 trial to evaluate the safety, efficacy, and cellular kinetics of YTB323 in adults with severe, refractory systemic lupus erythem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• YTB323

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING